All In Biotech

Free tool

FAERS Monitor: Lamisil

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020980 or its brand name (Lamisil, Terbinafine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,279

Serious

835

65% of reports

Hospitalization

330

Death reported

50

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective96
  • pruritus77
  • rash75
  • nausea68
  • fatigue63
  • pain62
  • dyspnoea56
  • ageusia50
  • diarrhoea47
  • headache47
  • weight decreased46
  • cough42
  • dysgeusia42
  • off label use42
  • dizziness40

Reports by year received

View as table
YearReports
200728
200826
200917
201026
201123
201238
201315
201416
201554
201625
201743
201856
201973
202063
202179
2022148
2023147
2024162
2025157
202683

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,880 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ageusiaSignal5033.025.21,520
dysgeusiaSignal429.36.9304
pruritusSignal773.32.7123
rashSignal752.82.389
weight decreasedSignal462.72.049
coughSignal422.51.836
pain621.71.316
dyspnoea561.61.313
nausea681.41.18
fatigue631.31.05
dizziness401.31.03
headache471.20.92
drug ineffective961.21.03
diarrhoea471.20.91
off label use420.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.